agalsidase alfa: clinical use

Prescribing considerations

• Initiate and supervise through a clinician experienced in Fabry disease or inherited metabolic disorders.
• Assess suitability carefully before transferring to home infusion or trained self-administration.
• Advanced renal damage may limit the renal response to enzyme replacement therapy.
• Infusion-related haemodynamic stress may trigger cardiac events in patients with cardiac manifestations of Fabry disease.
• Evidence in very young children, older adults and hepatic impairment is limited.

Contraindications and cautions

• Hypersensitivity to agalsidase alfa or any formulation excipient.

Monitoring

• Observe for infusion reactions and hypersensitivity, including delayed-onset reactions.
• Record the product name and batch number for biological traceability.
• Continue specialist assessment of Fabry-related renal, cardiac and neurological disease.
• Ensure adverse events during home administration prompt immediate cessation and clinical review.

Clinical pharmacology

Recombinant human alpha-galactosidase A produced in a human cell line. Cellular uptake is influenced by mannose-6-phosphate receptors; the enzyme hydrolyses Gb3 and is expected to undergo protein degradation by peptide hydrolysis, with renal elimination being a minor pathway.

Formulation and product differences

• The selected UK product is a clear, colourless concentrate requiring dilution in sodium chloride infusion solution.
• It is preservative-free, for single use and should be mixed gently rather than shaken.
• Administration requires an integral line filter; it must not be mixed with other medicines or infused through the same line.
• The concentrate requires refrigerated storage and contains sodium and polysorbate 20.

Solution for infusion

Route: Intravenous

Strengths: 1 mg/mL